$39.65
3.80% yesterday
Nasdaq, Nov 07, 10:00 pm CET
ISIN
US0327241065
Symbol
ANAB

AnaptysBio, Inc. Stock price

$39.65
+9.78 32.74% 1M
+19.97 101.47% 6M
+26.41 199.47% YTD
+18.16 84.50% 1Y
+10.56 36.30% 3Y
+10.03 33.86% 5Y
+22.65 133.24% 10Y
+22.65 133.24% 20Y
Nasdaq, Closing price Fri, Nov 07 2025
+1.45 3.80%
ISIN
US0327241065
Symbol
ANAB
Industry

Key metrics

Basic
Market capitalization
$1.1b
Enterprise Value
$832.1m
Net debt
positive
Cash
$265.7m
Shares outstanding
28.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
8.9 | 8.7
EV/Sales
6.8 | 6.6
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
14.7%
Return on Equity
-204.9%
ROCE
-28.7%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$123.2m | $125.5m
EBITDA
$-85.6m | $-81.5m
EBIT
$-86.1m | $-110.5m
Net Income
$-132.6m | $-118.9m
Free Cash Flow
$-128.1m
Growth (TTM | estimate)
Revenue
304.1% | 37.5%
EBITDA
47.1% | 28.7%
EBIT
47.0% | 3.9%
Net Income
22.1% | 18.1%
Free Cash Flow
1.4%
Margin (TTM | estimate)
Gross
-
EBITDA
-69.5% | -64.9%
EBIT
-69.9%
Net
-107.7% | -94.8%
Free Cash Flow
-104.0%
More
EPS
$-4.6
FCF per Share
$-4.6
Short interest
47.8%
Employees
136
Rev per Employee
$670.0k
Show more

Is AnaptysBio, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,024 stocks worldwide.

AnaptysBio, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

19 Analysts have issued a AnaptysBio, Inc. forecast:

16x Buy
84%
3x Hold
16%

Analyst Opinions

19 Analysts have issued a AnaptysBio, Inc. forecast:

Buy
84%
Hold
16%

Financial data from AnaptysBio, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
123 123
304% 304%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 46 46
8% 8%
37%
- Research and Development Expense 164 164
14% 14%
133%
-86 -86
47% 47%
-69%
- Depreciation and Amortization 0.58 0.58
9% 9%
0%
EBIT (Operating Income) EBIT -86 -86
47% 47%
-70%
Net Profit -133 -133
22% 22%
-108%

In millions USD.

Don't miss a Thing! We will send you all news about AnaptysBio, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

AnaptysBio, Inc. Stock News

Neutral
GlobeNewsWire
4 days ago
SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences: TD Cowen Im...
Neutral
GlobeNewsWire
4 days ago
Announced intent to separate biopharma operations from substantial royalty assets by YE 2026 Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on track for Nov./Dec. 2025 Phase 2b data for rosnilimab in rheumatoid arthritis featured as late-breaking oral presentation at ACR Convergence 2025 Phase 1b initiated in celiac disease for ANB033, ...
Neutral
GlobeNewsWire
10 days ago
SAN DIEGO, Oct. 29, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced late-breaking data from the robust, global 424-patient Phase 2b trial of rosnilimab, a selective and potent pathogenic T cell depleter, in rheumatoid arthritis (RA) at the American College of Rheumatology (...
More AnaptysBio, Inc. News

Company Profile

AnaptysBio, Inc. is a clinical stage biotechnology company, which engages in developing antibody product candidates focused on unmet medical needs in inflammation. Its products pipeline include ANB020, ANB019, and checkpoint receptor agonist antibodies. The company was founded by Andrew B. Cubitt, William J. Boyle and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Head office United States
CEO Daniel Faga
Employees 136
Founded 2005
Website www.anaptysbio.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today